Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Study of Participants With Advanced Non-Small Cell Lung Cancer

Phase 3

Completed

Conditions: Advanced Non-Small Cell Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Carboplatin
Drug: Paclitaxel
Biological: Bevacizumab

First Posted Date: 2009-07-29

Last Posted Date: 2021-10-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 361

Registration Number: NCT00948675

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kennewick, Washington, United States

S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Phase 3

Terminated

Conditions: Recurrent Lung Adenocarcinoma
Stage IV Squamous Cell Lung Carcinoma
Stage IV Lung Adenocarcinoma
Recurrent Squamous Cell Lung Carcinoma
Recurrent Large Cell Lung Carcinoma
Stage IV Large Cell Lung Carcinoma

Interventions: Biological: Bevacizumab
Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Biological: Cetuximab
Drug: Paclitaxel

First Posted Date: 2009-07-27

Last Posted Date: 2023-05-23

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 1333

Registration Number: NCT00946712

Locations: 🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸
Columbus CCOP, Columbus, Ohio, United States
🇺🇸
Grant Medical Center, Columbus, Ohio, United States

and more 787 locations

Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer Stage IV
Ovarian Cancer Stage IIIC

Interventions: Drug: CS-1008
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2009-07-24

Last Posted Date: 2021-04-08

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 24

Registration Number: NCT00945191

Locations: 🇺🇸
University of Oklahoma, Oklahoma City, Oklahoma, United States
🇺🇸
Barnes Jewish Hospital, Saint Louis, Missouri, United States
🇺🇸
Univ. Alabama, Birmingham, Alabama, United States

Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer

Phase 3

Conditions: Endometrial Clear Cell Adenocarcinoma
Endometrial Serous Adenocarcinoma
Stage IA Uterine Corpus Cancer AJCC v7
Stage IB Uterine Corpus Cancer AJCC v7
Stage IVA Uterine Corpus Cancer AJCC v7
Stage II Uterine Corpus Cancer AJCC v7
Stage IIIA Uterine Corpus Cancer AJCC v7
Stage IIIB Uterine Corpus Cancer AJCC v7
Stage IIIC Uterine Corpus Cancer AJCC v7

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Drug: Cisplatin
Radiation: Internal Radiation Therapy
Other: Quality-of-Life Assessment
Radiation: Radiation Therapy

First Posted Date: 2009-07-20

Last Posted Date: 2021-10-19

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 813

Registration Number: NCT00942357

Locations: 🇺🇸
Prisma Health Cancer Institute - Easley, Easley, South Carolina, United States
🇺🇸
Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States
🇺🇸
Grant Medical Center, Columbus, Ohio, United States

and more 663 locations

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Bevacizumab
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2009-07-13

Last Posted Date: 2017-11-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 190

Registration Number: NCT00937560

Locations: 🇳🇱
Mc Haaglanden, Locatie Antoniushove; Interne Geneeskunde, Leidschendam, Netherlands
🇮🇹
Universita' Cattolica Del Sacro Cuore; Reparto Ginecologia Oncologica, Campobasso, Molise, Italy
🇫🇷
Clinique Tivoli; Sce Radiotherapie, Bordeaux, France

and more 51 locations

Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary

Phase 2

Completed

Conditions: Carcinoma of Unknown Primary Origin

Interventions: Drug: carboplatin
Drug: everolimus
Drug: paclitaxel

First Posted Date: 2009-07-10

Last Posted Date: 2017-03-21

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 46

Registration Number: NCT00936702

Locations: 🇺🇸
CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States
🇺🇸
Cancer Center of Kansas-Independence, Independence, Kansas, United States
🇺🇸
Memorial Hospital of South Bend, South Bend, Indiana, United States

and more 136 locations

High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors

Phase 2

Completed

Conditions: Testicular Cancer

Interventions: Drug: Gemcitabine
Drug: Docetaxel
Drug: Mesna
Drug: Melphalan
Drug: Ifosfamide
Drug: Carboplatin
Drug: Etoposide
Procedure: Stem Cell Transplant

First Posted Date: 2009-07-10

Last Posted Date: 2024-08-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 64

Registration Number: NCT00936936

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Fred Hutchinson Cancer Center, Seattle, Washington, United States